

Table S4. KEGG analysis. Analysis of total DEGs and the subgroups of up- and down-regulated DEGs. Numbers in brackets indicate count of DEGs.

Analysis of Down-regulated DEGs						
hsa05200	Pathways in cancer	13	4.5	3.90E-02	2.80E-01	IL6, PTGER3, PTGS2, ROCK2, FGF9, RUNX1T1, FGF10, ZBTB16, FZD7, LAMA2, FOS, PTCH1, FGF2 (13)
hsa04022	cGMP-PKG signaling pathway	12	4.2	8.20E-05	8.10E-03	KCNMA1, ATP2B4, ROCK2, PLN, MRV11, PDE5A, CREB5, ATP1A2, MYLK, ITPR1, KCNMB1, MYL9 (12)
hsa04024	cAMP signaling pathway	11	3.8	2.20E-03	8.20E-02	FOS, PTGER3, ATP2B4, ROCK2, CAMK2G, PLN, ABCC4, CREB5, PTCH1, ATP1A2, MYL9 (11)
hsa04270	Vascular smooth muscle contraction	10	3.5	1.80E-04	8.70E-03	KCNMA1, ACTG2, ROCK2, CALD1, MRV11, PLA2G2A, MYLK, ITPR1, KCNMB1, MYL9 (10)
hsa04020	Calcium signaling pathway	10	3.5	3.70E-03	9.90E-02	PTGER3, ATP2B4, CHRM3, PDE1C, CAMK2G, PLN, PLCD4, PTGER, MYLK, ITPR1 (10)
hsa05205	Proteoglycans in cancer	10	3.5	7.60E-03	1.50E-01	GPC3, ROCK2, CAMK2G, HBEGF, PTCH1, FLNC, FGF2, FZD7, FLNA, ITPR1 (10)
hsa04510	Focal adhesion	10	3.5	9.20E-03	1.70E-01	LAMA2, ROCK2, ITGA8, ILK, ACTN1, FLNC, FLNA, MYLK, MYL9, VCL (10)
hsa04810	Regulation of actin cytoskeleton	10	3.5	1.00E-02	1.60E-01	CHRM3, ROCK2, FGF9, ITGA8, ACTN1, FGF10, FGF2, MYLK, MYL9, VCL (10)
hsa04010	MAPK signaling pathway	10	3.5	3.10E-02	2.60E-01	FOS, NTF3, FGF9, MAPT, CACNB2, FGF10, GADD45B, FLNC, FGF2, FLNA (10)
hsa05410	Hypertrophic cardiomyopathy (HCM)	9	3.1	5.40E-05	1.10E-02	IL6, ACTC1, DES, DMD, ITGA8, CACNB2, TPM2, TPM1, SGCA (9)